

# **BIO USAWA INC. WELCOMES VINCE ANICETTI TO THE BOARD OF DIRECTORS**

**April 11, 2024: Kigali, Rwanda and San Francisco, USA**

Bio Usawa Inc. (BUI) is excited to welcome Vince Anicetti to its Board of Directors. Bringing over four decades of expertise and leadership in the biopharmaceutical industry, Anicetti's addition signifies a pivotal moment in BUI's journey towards making high-quality, affordable healthcare accessible across Africa. Anicetti will serve as the Chairman of the Manufacturing Advisory Board for BUI.

As one of its earliest hires, Vince Anicetti had a 30-year career at Genentech, the premier company in the manufacturing of monoclonal antibodies, where he held senior executive roles in Quality, Regulatory Affairs, Product Development, and Operations. He ultimately served as Vice President of Biologics Quality for Genentech and Roche global biologics manufacturing operations. This experience has equipped Anicetti with an unparalleled depth of knowledge in biologics' quality assurance and global manufacturing oversight. Anicetti subsequently held senior executive roles at Boehringer Ingelheim and later as COO at Coherus Biosciences. Anicetti continues as a strategic advisor with Coherus and sits on advisory boards for Allakos Inc. and Gore. His commitment to education and industry standards shines through his adjunct professorship at the Keck Graduate Institute and his service on the boards of the Parenteral Drug Association and the San Francisco State University Foundation.

Dr. Menghis Bairu, Co-founder and CEO of BUI, remarked, "Our journey towards healthcare equity in Africa is greatly enhanced with Vince Anicetti on board. Vince's unparalleled experience and leadership in biopharmaceutical quality and regulatory affairs make him an invaluable addition to our board. His vision aligns perfectly with our mission to revolutionize healthcare access across Africa."

"It is a privilege to join Bio Usawa and its effort to bring affordable biologic medicines to Africa," commented Anicetti. "We will use the technological advances of the past four decades to build and operate large-scale, state-of-the-art biologic manufacturing plants in Africa that will enable Bio Usawa to dramatically reduce costs and logistics while ensuring the highest product quality. I look forward to the day when our facilities are on-line and providing lifesaving medicines produced in Africa for patients in Africa and beyond."

The Bio Usawa team extends a warm welcome to Vince Anicetti, looking forward to his contributions in shaping a healthier future for Africa.

## **About Bio Usawa Inc.**

Bio Usawa Inc. is at the forefront of transforming healthcare access across Africa through the local production and distribution of affordable monoclonal antibodies. With a profound commitment to public health, BUI aims to become the leading supplier of therapeutic monoclonal antibodies in Africa, ensuring no patient is left without essential treatments due to cost barriers.



**WHEN PATIENTS DIE BECAUSE THERE IS NO CURE, IT'S A TRAGEDY; WHEN THEY DIE EVEN WHEN THERE IS AN EFFECTIVE CURE BECAUSE OF THE COST, IT IS INJUSTICE.**